130 related articles for article (PubMed ID: 18490922)
1. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.
Lin SH; Cheng CJ; Lee YC; Ye X; Tsai WW; Kim J; Pasqualini R; Arap W; Navone NM; Tu SM; Hu M; Yu-Lee LY; Logothetis CJ
Oncogene; 2008 Sep; 27(39):5195-203. PubMed ID: 18490922
[TBL] [Abstract][Full Text] [Related]
2. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells.
Chen N; Ye XC; Chu K; Navone NM; Sage EH; Yu-Lee LY; Logothetis CJ; Lin SH
Cancer Res; 2007 Jul; 67(14):6544-8. PubMed ID: 17638862
[TBL] [Abstract][Full Text] [Related]
3. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.
Lin SH; Lee YC; Choueiri MB; Wen S; Mathew P; Ye X; Do KA; Navone NM; Kim J; Tu SM; Yu-Lee LY; Logothetis CJ
Clin Cancer Res; 2008 Jun; 14(12):3729-36. PubMed ID: 18559590
[TBL] [Abstract][Full Text] [Related]
4. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
5. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.
Larson SR; Chin J; Zhang X; Brown LG; Coleman IM; Lakely B; Tenniswood M; Corey E; Nelson PS; Vessella RL; Morrissey C
Clin Exp Metastasis; 2014 Feb; 31(2):247-56. PubMed ID: 24242705
[TBL] [Abstract][Full Text] [Related]
7. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein.
Dai J; Kitagawa Y; Zhang J; Yao Z; Mizokami A; Cheng S; Nör J; McCauley LK; Taichman RS; Keller ET
Cancer Res; 2004 Feb; 64(3):994-9. PubMed ID: 14871830
[TBL] [Abstract][Full Text] [Related]
10. The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches.
Özdemir BC; Hensel J; Secondini C; Wetterwald A; Schwaninger R; Fleischmann A; Raffelsberger W; Poch O; Delorenzi M; Temanni R; Mills IG; van der Pluijm G; Thalmann GN; Cecchini MG
PLoS One; 2014; 9(12):e114530. PubMed ID: 25485970
[TBL] [Abstract][Full Text] [Related]
11. Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.
Elshafae SM; Dirksen WP; Alasonyalilar-Demirer A; Breitbach J; Yuan S; Kantake N; Supsavhad W; Hassan BB; Attia Z; Alstadt LB; Rosol TJ
Prostate; 2020 Jun; 80(9):698-714. PubMed ID: 32348616
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer cells promote osteoblastic bone metastases through Wnts.
Hall CL; Bafico A; Dai J; Aaronson SA; Keller ET
Cancer Res; 2005 Sep; 65(17):7554-60. PubMed ID: 16140917
[TBL] [Abstract][Full Text] [Related]
13. Canine prostate induces new bone formation in mouse calvaria: A model of osteoinduction by prostate tissue.
LeRoy BE; Bahnson RR; Rosol TJ
Prostate; 2002 Feb; 50(2):104-11. PubMed ID: 11816018
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.
Yang J; Fizazi K; Peleg S; Sikes CR; Raymond AK; Jamal N; Hu M; Olive M; Martinez LA; Wood CG; Logothetis CJ; Karsenty G; Navone NM
Cancer Res; 2001 Jul; 61(14):5652-9. PubMed ID: 11454720
[TBL] [Abstract][Full Text] [Related]
16. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis.
Rubin J; Chung LW; Fan X; Zhu L; Murphy TC; Nanes MS; Rosen CJ
Prostate; 2004 Jan; 58(1):41-9. PubMed ID: 14673951
[TBL] [Abstract][Full Text] [Related]
17. p65-Dependent production of interleukin-1β by osteolytic prostate cancer cells causes an induction of chemokine expression in osteoblasts.
Schulze J; Weber K; Baranowsky A; Streichert T; Lange T; Spiro AS; Albers J; Seitz S; Zustin J; Amling M; Fehse B; Schinke T
Cancer Lett; 2012 Apr; 317(1):106-13. PubMed ID: 22108531
[TBL] [Abstract][Full Text] [Related]
18. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells.
Cheng CJ; Ye XC; Vakar-Lopez F; Kim J; Tu SM; Chen DT; Navone NM; Yu-Lee LY; Lin SH; Hu MC
Mol Cancer Res; 2007 Jul; 5(7):675-84. PubMed ID: 17634423
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.
Li ZG; Yang J; Vazquez ES; Rose D; Vakar-Lopez F; Mathew P; Lopez A; Logothetis CJ; Lin SH; Navone NM
Oncogene; 2008 Jan; 27(5):596-603. PubMed ID: 17700537
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
Delliaux C; Tian TV; Bouchet M; Fradet A; Vanpouille N; Flourens A; Deplus R; Villers A; Leroy X; Clézardin P; de Launoit Y; Bonnelye E; Duterque-Coquillaud M
Cancer Lett; 2018 Dec; 438():32-43. PubMed ID: 30201302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
